Early Statin Use Linked to Lower Dementia Risk
Starting statins soon after being diagnosed with type 2 diabetes has been linked to a 15% lower relative risk of developing dementia over 10 years, according to a large nationwide study.
Researchers examined health records from 132,585 people in Denmark who developed type 2 diabetes between 2006 and 2019 and had not previously taken statins.
Participants were divided according to when they started statin treatment.
Researchers classified those who began taking statins within one year of their diabetes diagnosis as early users, while those who started between one and five years later were classified as late users. They were compared with people who did not begin statins within five years.
The findings were striking.
Early statin treatment was associated with a 15% lower relative risk of dementia over 10 years compared with no statin initiation, while starting treatment later was associated with a 10% lower relative risk.
The research adds to growing interest in the relationship between cardiovascular health and brain health.
However, scientists stress that this was an observational study. It cannot establish that statins themselves caused the reduction in dementia risk.
How Big Was the Study?
The scale of the research is one of its strengths.
Scientists used Denmark’s nationwide health registers to identify 132,585 statin-naive people who developed type 2 diabetes between 2006 and 2019.
Participants were followed until they developed dementia, died, emigrated or reached the end of the study period on December 31, 2021.
The median follow-up was 7.1 years.
During that period, 3,592 people — around 2.7% of participants — developed dementia.
Researchers then estimated the participants’ dementia risk over a 10-year period according to when statin therapy began.
The estimated 10-year dementia risk was:
- 3.9% among those who did not initiate statins within five years.
- 3.5% among people who started statins between one and five years after diagnosis.
- 3.3% among those who started within the first year.
That final figure translates into a 15% relative reduction compared with the group that did not start statin treatment.
Relative Risk and Absolute Risk Are Different
The phrase “15% lower dementia risk” can sound larger than the underlying absolute difference, so understanding the numbers is important.
The estimated 10-year dementia risk declined from 3.9% without statin initiation to 3.3% with early initiation.
That represents an absolute difference of about 0.59 percentage points.
In simple terms, that is approximately six fewer dementia cases for every 1,000 people over the period examined.
The 15% figure describes the relative difference between the groups, rather than meaning that 15 out of every 100 people taking statins avoided dementia.
Both measurements are useful, but they describe the findings differently.
Why Were People With Type 2 Diabetes Studied?
People with type 2 diabetes are particularly important when researchers investigate dementia prevention.
Diabetes affects blood vessels throughout the body, including those supplying the brain.
Over time, high blood sugar, high blood pressure and abnormal cholesterol levels can contribute to cardiovascular and vascular damage.
People with diabetes also have an elevated risk of cardiovascular disease.
Because vascular health and brain health are closely connected, researchers have become increasingly interested in whether aggressively managing cardiovascular risk factors could also reduce the likelihood of dementia.
That is where statins become particularly interesting.
What Are Statins?
Statins are medications primarily used to lower cholesterol.
They reduce the production of cholesterol in the liver and are particularly effective at lowering low-density lipoprotein cholesterol, commonly known as LDL or “bad” cholesterol.
High LDL levels can contribute to fatty deposits accumulating inside arteries.
Over time, these deposits can restrict blood flow and increase the risk of heart attacks and strokes.
Statins are therefore commonly prescribed to people considered at increased cardiovascular risk, including many people with diabetes.
The drugs are already well established for preventing cardiovascular disease in appropriate patients.
The question raised by the latest research is whether earlier treatment might also have long-term implications for brain health.
Why Could Lower Cholesterol Protect the Brain?
Scientists have several possible explanations.
The brain depends on a healthy supply of blood and oxygen.
Damage to blood vessels can contribute to strokes and smaller vascular injuries that may gradually affect cognitive function.
Lowering LDL cholesterol reduces cardiovascular risk and could therefore indirectly protect the brain by maintaining healthier blood vessels.
Researchers are also investigating connections between cholesterol metabolism, inflammation and neurodegenerative processes.
But the exact biological relationship between statins and dementia remains uncertain.
The Danish study was designed to examine the association between the timing of statin treatment and dementia risk rather than determine precisely how statins might produce a protective effect.
Mechanisms of Vascular-Driven Brain Health
| Component | Role in the Axis | Impact of Unmanaged Cholesterol |
|---|---|---|
| Cardiovascular System | Pumps oxygenated blood throughout the body. | Reduced pumping efficiency due to arterial stiffness. |
| Blood Vessels | Blood vessels act as a transport medium to the central nervous system. | Plaque accumulation, narrowing, and potential blockages. |
| The Brain | The brain is dependent on a continuous vascular supply. | Ischaemic white matter changes, cell loss, and cognitive decline |
Starting Earlier Was Associated With the Biggest Difference
Timing was one of the most interesting aspects of the study.
People beginning statin treatment within one year of their type 2 diabetes diagnosis had the lowest estimated dementia risk.
Those starting between one and five years later also had a lower risk than people who did not start treatment, but the association was smaller.
Early initiation was associated with a 15% lower relative risk, compared with 10% for later initiation.
This stepwise pattern raises the possibility that controlling cardiovascular risk factors earlier could provide greater long-term benefits.
Researchers found broadly similar patterns in men and women.
Does This Prove Statins Prevent Dementia?
No.
This is probably the most important limitation to understand.
The study was observational, not a randomised clinical trial.
Researchers used sophisticated statistical techniques designed to emulate some features of a randomised trial, but participants were not randomly assigned to take or avoid statins.
That means other differences between people who received early treatment and those who did not could potentially have influenced the results.
For example, patients beginning treatment early may differ in their healthcare engagement, medical history or other behaviours.
Researchers attempted to account for potential biases, but observational research cannot eliminate them.
The authors therefore concluded that trial evidence is needed to confirm the findings.
Should People Start Statins to Prevent Dementia?
The study should not be interpreted as a recommendation for everyone to start taking statins specifically to prevent dementia.
Statins are prescription medicines, and whether someone should take them depends on their individual cardiovascular risk, cholesterol levels, medical history and other factors.
The established reason for prescribing statins remains the prevention of cardiovascular disease in people for whom treatment is appropriate.
The dementia findings provide an intriguing additional possibility, but they are not yet proof of a dementia-prevention treatment.
People should therefore discuss statin treatment with their doctor or another qualified healthcare professional rather than starting, stopping or changing medication based on this study alone.
What About Concerns That Statins Harm Memory?
Statins and cognitive health have generated debate for years.
Some people have worried that cholesterol-lowering drugs might negatively affect memory or increase dementia risk.
Scientific evidence has not established that statins cause dementia.
Research examining the issue has produced varying results depending on study design and population, and scientists continue to investigate the relationship.
The new Danish findings add evidence suggesting that statin treatment may instead be associated with lower dementia risk in a specific high-risk population — people developing type 2 diabetes.
But that does not mean every person taking a statin receives the same neurological benefit.
Why Cardiovascular Health Matters for Dementia
The research also highlights a broader development in dementia science.
Scientists increasingly recognise that dementia prevention cannot be separated from overall health.
Blood pressure, diabetes, cholesterol, smoking, physical inactivity and obesity can influence cardiovascular health, and several of these factors have also been associated with dementia risk.
Protecting blood vessels throughout adulthood may therefore help protect the brain later in life.
This does not mean dementia can always be prevented.
Age, genetics, and biological processes that are beyond an individual’s control remain important.
But identifying modifiable risk factors provides researchers potential opportunities to delay or reduce some cases.
Study Presented at ESC Congress 2026
The research was presented at ESC Congress 2026 and published in The Lancet Regional Health – Europe.
Researchers from Denmark used national health data covering more than a decade.
The study was funded by the Danish Cardiovascular Academy and the Danish Heart Foundation.
Its lead researchers emphasised that statins are already known to protect against cardiovascular disease and suggested that the dementia association provides another reason to investigate the benefits of timely cholesterol management in people with type 2 diabetes.
Crucially, they also called for randomised trial evidence to establish whether the association is genuinely causal.
Could Future Research Change Dementia Prevention?
Potentially.
If future randomised trials confirm that early cholesterol-lowering treatment directly reduces dementia risk, the findings could have important implications.
Millions of people worldwide live with type 2 diabetes.
Even a relatively modest reduction in dementia risk could therefore translate into a meaningful number of cases at the population level.
Researchers will need to determine whether the apparent protection comes directly from statins, from lower LDL cholesterol, from improved vascular health or from a combination of mechanisms.
They will also need to establish whether similar effects occur among people without diabetes.
Until then, the findings should be regarded as promising evidence rather than definitive proof.
Conclusion
The finding that early statin use was linked to a 15% lower dementia risk provides another intriguing connection between cardiovascular health and the ageing brain.
In a nationwide study involving more than 132,000 people with newly diagnosed type 2 diabetes, starting statins within one year was associated with the lowest estimated dementia risk over the following decade.
The estimated 10-year risk was 3.3% among early statin users compared with 3.9% among those who did not initiate statins within five years.
Starting treatment later was also associated with lower risk, although the difference was smaller.
The results are encouraging, but they do not prove that statins prevent dementia.
For now, the strongest conclusion is that managing cardiovascular risk early — particularly in people with type 2 diabetes — may have benefits that extend beyond the heart.
Further randomised clinical trials will be needed to determine whether protecting cardiovascular health with statins can directly help protect the brain as well
Medical note: This article is for general information and does not replace individual medical advice.
Make sure our latest headlines always appear at the top of your Google searches by adding us as a favourite source. Click here to activate. Or add us as your preferred source to your Google Search settings
